Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients

Saudi Medical Journal

Volumn 25, Issue 11, 2004, Pages 1587-1592

  Kara, Ismail O ^a   Sahin, Berksoy ^a   Paydas, Semra ^a   Cetiner, Salih ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; EOSIN; HEMATOXYLIN; MELPHALAN; SYNDECAN 1; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MALE; MICROSCOPY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PARAMETRIC TEST; PATIENT CODING; PLASMA CELL; SAMPLE; SEX RATIO; STATISTICAL SIGNIFICANCE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ADP-RIBOSYL CYCLASE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, CD38; ANTIGENS, CD45; ANTIGENS, CD56; BONE MARROW CELLS; BONE MARROW NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; PLASMA CELLS; PROTEOGLYCANS; SAUDI ARABIA; STATISTICS; SYNDECAN-1; SYNDECANS;

EID: 10644256584     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ruiz AG, San MJ. Cell surface markers in multiple myeloma. Mayo Clin Proc 1994; 69: 684-690.
2. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658-2663.
3. Zandecki M, Facon T, Bernardi F, Izydorczyk V, Dupond L, Francois M, et al. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance. J Clin Pathol 1995; 48: 548-552.
4. Van Riet I. Homing mechanisms of myeloma cells. Pathol Biol Paris 1999; 47: 98-108.
5. Kyle RA. Benign monoclonal gammopathy-after 20-35 years of follow-up. Mayo Clin Proc 1993; 68: 26-32.
6. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100: 637-646.
7. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, et al. CD138/syndecan-1: A useful immunohistochemical marker of normal and neoplastic plasma cells routine trephine bone marrow biopsies. Mod Pathol 1999; 12: 1101-1106.
8. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD, et al. Elevated levels of shed syndecan-1 correlate strongly with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 1997; 99: 368-371.
9. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, et al. Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 2000; 95: 388-392.
10. Kaushal GP, Xiong X, Athota AB, Rozypal TL, Sanderson RD, Kelly T. Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase-9. Br J Haematol 1999; 104: 365-373.
11. Wei A, Juneja S. Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol 2003; 56: 406-411.
12. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94: 318-323.
13. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94: 701-712.
14. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97: 1817-1822.
15. Calame KL. Plasma cells: finding new light at the end of B cell development. Nat Immunol 2001; 2: 1103-1108.
16. Pellat DC, Barille S, Puthier D, Rapp MJ, Harrousseau JL, Bataille R, et al. Adhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647-3653.
17. Luque R, Brieva JA, Moreno A, Manzanal A, Escribano L, Villarrubia J, et al. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients-diagnostic and clinical implications. Clin Exp Immunol 1998; 112: 410-418.
18. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29-35.
19. Ashcroft J, Rawstron AC, Owen RG, Morgan GJ. Phenotyping in myeloma: identification of a rare CD19+56-subgroup. Blood 2000; 96: 156a.
20. Pope B, Brown RD, Gibson J, Petersen A, Wiley J, Joshua DE. The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. Leak Lymphoma 1b] 1997; 27: 83-91.
21. Epstein J. Myeloma stem cell phenotype. Implication for treatment. Hematol Oncol Clin North Am 1997; 11: 43-49.
22. Hata H, Xiao HQ, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature myeloma cells. Blood 1993; 81: 3357-3364.
23. Jensen GS, Mant MJ, Pilarski LM. Sequential maturation stages of monoclonal B lineage cells from blood, spleen, lymph node, and bone marrow from a terminal myeloma patient. Am J Haematol 1992; 41: 199-208.
24. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmocytes are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999; 94: 701-712.
25. Jego G, Batallie R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plasmablasts. Blood 2001; 97: 1818-1822.
26. Fuji R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1-CD49e-immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 1999; 105: 131-140.
27. Thomas X, Xiao HQ, Chang R, Epstein J. Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. Curr Top Microbiol Immunol 1992; 182: 201-207.
28. Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE, et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, clg+ is the common phenotype of myeloma. cells. Ann Hematol 1992; 64:132-139.
29. Ocqueteau M, Orfao A, Almeida J, Blade J, Gonzalez M, Garcia-Sanz R, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients-implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655-1665.
30. Sonneveld P, Durie B, Lokhorst H, Frutiger Y, Schoester M, Vela EE. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol 1993; 83: 63-67.
31. Fields RD, Itoh K. Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Trends Neurosci 1996; 19: 473-480.
32. Witzig TE, Kimlinger T, Stenson M, Themeau T. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31: 167-175.
33. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol 1997; 97: 46-55.
34. Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: Clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93: 1032-1037.
35. Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia1998; 12: 1977-1982.
36. Oivanen TM. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 1996; 92: 834-839.
37. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998; 91: 3518-3523.